Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Humby, Frances, Durez, Patrick, Buch, Maya H, Lewis, Myles J, Rizvi, Hasan, Rivellese, Felice, Nerviani, Alessandra, Giorli, Giovanni, Mahto, Arti, Montecucco, Carlomaurizio, Lauwerys, Bernard, Ng, Nora, Ho, Pauline, Bombardieri, Michele, Romão, Vasco C, Verschueren, Patrick, Kelly, Stephen, Sainaghi, Pier Paolo, Gendi, Nagui, Dasgupta, Bhaskar, Cauli, Alberto, Reynolds, Piero, Cañete, Juan D, Moots, Robert, Taylor, Peter C, Edwards, Christopher J, Isaacs, John, Sasieni, Peter, Choy, Ernest, Pitzalis, Costantino
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7829614/
https://ncbi.nlm.nih.gov/pubmed/33485455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(20)32341-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados